Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | PROKR1 | Q8TCW9 | 11/20 | 0.39 |
| ▸ | BTK | Q06187 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26647696 | 1.00 | JAK2 (0.45) | JAK2JAK1JAK3GSK3BPROKR1 | |
| SCHEMBL26772556 | 0.84 | PRMT5 (0.49) | JAK2JAK1PRMT5 | |
| SCHEMBL26647694 | 0.81 | JAK2 (0.52) | JAK2JAK1JAK3 | |
| SCHEMBL26647690 | 0.81 | JAK2 (0.52) | JAK2JAK1JAK3 | |
| SCHEMBL23397594 | 0.78 | JAK2 (0.39) | JAK2JAK1JAK3LMNAHTT | |
| SCHEMBL22205434 | 0.78 | JAK2 (0.39) | JAK2JAK1JAK3LMNAHTT | |
| SCHEMBL22205435 | 0.78 | JAK2 (0.39) | JAK2JAK1JAK3LMNAHTT | |
| SCHEMBL22205436 | 0.78 | JAK2 (0.39) | JAK2JAK1JAK3LMNAHTT | |
| SCHEMBL23397595 | 0.78 | JAK2 (0.39) | JAK2JAK1JAK3LMNAHTT | |
| SCHEMBL29189096 | 0.77 | JAK1 (0.42) | JAK2JAK1JAK3GSK3BPROKR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365534-A1 | MODULATORS OF NLRP3 INFLAMMASOME AND RELATED PRODUCTS AND METHODS | Neumora Therapeutics, Inc. | 2023-11-16 | — | — | US | disclosed |
| WO-2023220408-A1 | MODULATORS OF NLRP3 INFLAMMASOME AND RELATED PRODUCTS AND METHODS | Neumora Therapeutics, Inc. (US) | 2023-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365534-A1 | MODULATORS OF NLRP3 INFLAMMASOME AND RELATED PRODUCTS AND METHODS | NLRP3, NLRP1, PYCARD | JAK2 1484/4885JAK1 2294/4885JAK3 1802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.